When to initiate antiretroviral therapy in HIV-infected children?;Infection à VIH de l'enfant : Quand débuter le traitement antirétroviral ?

Archives de Pediatrie

Volumn 11, Issue 12, 2004, Pages 1521-1524

  Thuret, I ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Antiretroviral therapy; Children; HIV infection; Infants

Indexed keywords

ANTIRETROVIRUS AGENT;

BRAIN DISEASE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; NONHUMAN; REVIEW; SYMPTOM; VIRUS LOAD; VIRUS REPLICATION;

EID: 11144239678     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2004.01.019     Document Type: Article

References (11)

1. De Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;284:190-7.
2. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-8.
3. Soh C-H, Oleske JM, Brady MT, Spector SA, Borkowsky, Burchett SK, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet 2003;362:2045-51.
4. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. The Lancet infectious diseases 2002;2:93-102.
5. Mofenson LN, Korelitz J, Meyer WA, Bethel J, Rich K, et al. The relationship between serum human HIV-1 RNA level, CD4 lymphocyte percent, and long term mortality risk in HIV-1 infected children. JID 1997;175:1029-38.
6. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Disease progression in HIV-infected infants and children: predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count. JAMA 1998;279:756-61.
7. Short-term risk of disease progression in HIV-1infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003;362:1605-11 HIV Paediatric Prognostic Markers Collaborative Study Group.
8. Nikolic-Djokic D, Essajee S, Rigaud M, Kaul A, Chandwani S, Hoover W, et al. Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4 cell percentage at baseline. JID 2002;185:290-8.
9. Prise en charge des personnes infectées par le VIH. Rapport 2002, sous la direction du Pr JF Delfraissy. Médecine-Sciences Flammarion.
10. Abrams EJ, Wiener J, Carter R, Kuhn L, Palumbo P, Nesheim S, et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 2003;17:867-77.
11. Faye A, Lechenadec J, Dollfus C, Thuret I, Douard D, Firtion G et al. Early versus deferred antiretroviral multitherapy in Human Immunodeficiency Type-1 infected infants. Soumis.